Pharma major Lupin Limited (Lupin) announced the launch of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, having received an approval from the United Stat es Food and Drug Admini stration (U.S. FDA) earlier. The product would be manufactured at Lupin's Pithampur (Unit III) facility, India.
Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, is the generic equivalent of Diprolene® Ointment, 0.05%, of Merck Sharp and Dohme Corp. It is a corticosteroid indicated for t he relief of the inflam matory and pruritic manifestations of corticosteroid - responsive dermatoses in patients 13 years of age and older.
Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, (RLD: Diprolene®) had an annual sales of approximately USD 21 million in the U.S. (IQVIA MAT Jan uary 2020).
Shares of LUPIN LTD. was last trading in BSE at Rs.641.6 as compared to the previous close of Rs. 634.05. The total number of shares traded during the day was 119680 in over 3781 trades.
The stock hit an intraday high of Rs. 665 and intraday low of 620. The net turnover during the day was Rs. 77547058.